Literature DB >> 27399050

Synthesis of Kappa Opioid Antagonists Based On Pyrrolo[1,2-α]quinoxalinones Using an N-Arylation/Condensation/Oxidation Reaction Sequence.

Sarah M Scarry1, Kimberly M Lovell2, Kevin J Frankowski1, Laura M Bohn2, Jeffrey Aubé1.   

Abstract

The quinoxaline and quinoxalinone family of nitrogen heterocycles is present in molecules of therapeutic relevance for diverse applications ranging from infectious diseases to neuroscience targets. Here, we describe a general synthetic sequence to afford pyrrolo[1,2-α]quinoxalinones from commercially available starting materials and their use in preparing potential kappa opioid receptor antagonists. The biological data obtained from the latter set of compounds is briefly presented and discussed.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27399050      PMCID: PMC5278949          DOI: 10.1021/acs.joc.6b01350

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  14 in total

1.  Structure-activity relationships in the binding of chemically derivatized CD4 to gp120 from human immunodeficiency virus.

Authors:  Hui Xie; Danny Ng; Sergey N Savinov; Barna Dey; Peter D Kwong; Richard Wyatt; Amos B Smith; Wayne A Hendrickson
Journal:  J Med Chem       Date:  2007-09-06       Impact factor: 7.446

2.  Discovery of N-{4-[(3-hydroxyphenyl)-3-methylpiperazin-1-yl]methyl-2-methylpropyl}-4-phenoxybenzamide analogues as selective kappa opioid receptor antagonists.

Authors:  Chad M Kormos; Chunyang Jin; Juan Pablo Cueva; Scott P Runyon; James B Thomas; Lawrence E Brieaddy; S Wayne Mascarella; Hernán A Navarro; Brian P Gilmour; F Ivy Carroll
Journal:  J Med Chem       Date:  2013-05-16       Impact factor: 7.446

3.  Pyrroloquinoxaline derivatives as high-affinity and selective 5-HT(3) receptor agonists: synthesis, further structure-activity relationships, and biological studies.

Authors:  G Campiani; E Morelli; S Gemma; V Nacci; S Butini; M Hamon; E Novellino; G Greco; A Cagnotto; M Goegan; L Cervo; F Dalla Valle; C Fracasso; S Caccia; T Mennini
Journal:  J Med Chem       Date:  1999-10-21       Impact factor: 7.446

4.  Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent.

Authors:  G Campiani; F Aiello; M Fabbrini; E Morelli; A Ramunno; S Armaroli; V Nacci; A Garofalo; G Greco; E Novellino; G Maga; S Spadari; A Bergamini; L Ventura; B Bongiovanni; M Capozzi; F Bolacchi; S Marini; M Coletta; G Guiso; S Caccia
Journal:  J Med Chem       Date:  2001-02-01       Impact factor: 7.446

5.  Quinoxalin-2(1H)-one derivatives as inhibitors against hepatitis C virus.

Authors:  Rui Liu; Zhuhui Huang; Michael G Murray; Xiaoyong Guo; Gang Liu
Journal:  J Med Chem       Date:  2011-08-01       Impact factor: 7.446

6.  One-pot synthesis of pyrrolo[1,2-a]quinoxalines.

Authors:  Aiping Huang; Feng Liu; Chunjing Zhan; Yanli Liu; Chen Ma
Journal:  Org Biomol Chem       Date:  2011-09-06       Impact factor: 3.876

7.  Synthesis of novel quinoxaline derivatives and its cytotoxic activities.

Authors:  Shinji Tanimori; Takeshi Nishimura; Mitsunori Kirihata
Journal:  Bioorg Med Chem Lett       Date:  2009-06-06       Impact factor: 2.823

8.  Tetrahydropyrrolo[1,2-a]quinoxalines and tetrahydropyrrolo[1,2-a]pyrido[3,2-a]pyrazines: vascular smooth muscle relaxants and antihypertensive agents.

Authors:  M Abou-Gharbia; M E Freed; R J McCaully; P J Silver; R L Wendt
Journal:  J Med Chem       Date:  1984-12       Impact factor: 7.446

9.  Development of functionally selective, small molecule agonists at kappa opioid receptors.

Authors:  Lei Zhou; Kimberly M Lovell; Kevin J Frankowski; Stephen R Slauson; Angela M Phillips; John M Streicher; Edward Stahl; Cullen L Schmid; Peter Hodder; Franck Madoux; Michael D Cameron; Thomas E Prisinzano; Jeffrey Aubé; Laura M Bohn
Journal:  J Biol Chem       Date:  2013-11-01       Impact factor: 5.157

10.  Synthesis and SAR of novel tricyclic quinoxalinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1).

Authors:  Julie Miyashiro; Keith W Woods; Chang H Park; Xuesong Liu; Yan Shi; Eric F Johnson; Jennifer J Bouska; Amanda M Olson; Yan Luo; Elizabeth H Fry; Vincent L Giranda; Thomas D Penning
Journal:  Bioorg Med Chem Lett       Date:  2009-06-13       Impact factor: 2.823

View more
  1 in total

1.  Structurally Related Kappa Opioid Receptor Agonists with Substantial Differential Signaling Bias: Neuroendocrine and Behavioral Effects in C57BL6 Mice.

Authors:  Amelia D Dunn; Brian Reed; Catherine Guariglia; Alexandra M Dunn; Joshua M Hillman; Mary Jeanne Kreek
Journal:  Int J Neuropsychopharmacol       Date:  2018-09-01       Impact factor: 5.176

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.